230 related articles for article (PubMed ID: 17563252)
1. Intervening in the neuropsychiatric features of Parkinson's disease.
Weintraub D; Stern MB
Expert Rev Neurother; 2007 Jun; 7(6):699-710. PubMed ID: 17563252
[TBL] [Abstract][Full Text] [Related]
2. Management of the behavioral aspects of Parkinson's disease.
Borek LL; Chou KL; Friedman JH
Expert Rev Neurother; 2007 Jun; 7(6):711-25. PubMed ID: 17563253
[TBL] [Abstract][Full Text] [Related]
3. Psychosis in Parkinson's disease: how should we treat it?
Shotbolt P; Samuel M; Anthony D
Expert Rev Neurother; 2006 Sep; 6(9):1243-6. PubMed ID: 17009911
[No Abstract] [Full Text] [Related]
4. [Psychiatric complications of Parkinson's disease: their symptoms and treatment].
Castro-García A; Sesar-Ignacio A; Ares-Pensado B
Rev Neurol; 2004 Oct 1-15; 39(7):646-50. PubMed ID: 15490352
[TBL] [Abstract][Full Text] [Related]
5. [Emotional and cognitive disorders in Parkinson disease].
Arsland D; Larsen JP
Tidsskr Nor Laegeforen; 1998 Oct; 118(25):3959-63. PubMed ID: 9830342
[TBL] [Abstract][Full Text] [Related]
6. Cognitive, affective, and psychiatric features of Parkinson's disease.
Barbas NR
Clin Geriatr Med; 2006 Nov; 22(4):773-96, v-vi. PubMed ID: 17000335
[TBL] [Abstract][Full Text] [Related]
7. [Neuropsychiatric and cognitive symptoms in Parkinson disease].
Aarsland D; Pedersen KF; Ehrt U; Bronnick K; Gjerstad MD; Larsen JP
Tidsskr Nor Laegeforen; 2008 Sep; 128(18):2072-6. PubMed ID: 18846124
[TBL] [Abstract][Full Text] [Related]
8. Incidence, prescription patterns, and determinants of antipsychotic use in patients with Parkinson's disease.
Wang MT; Lian PW; Yeh CB; Yen CH; Ma KH; Chan AL
Mov Disord; 2011 Aug; 26(9):1663-9. PubMed ID: 21630354
[TBL] [Abstract][Full Text] [Related]
9. Anxiety, depression, and psychosis in Parkinson's disease: unmet needs and treatment challenges.
Chen JJ
Neurol Clin; 2004 Oct; 22(3 Suppl):S63-90. PubMed ID: 15501367
[No Abstract] [Full Text] [Related]
10. [Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment].
Thobois S; Ardouin C; Schmitt E; Lhommée E; Klinger H; Xie J; Lagrange C; Kistner A; Aya Kombo M; Fleury V; Poisson A; Fraix V; Broussolle E; Pollak P; Krack P
Rev Neurol (Paris); 2010 Oct; 166(10):816-21. PubMed ID: 20739041
[TBL] [Abstract][Full Text] [Related]
11. Neuropsychiatric complications of medical and surgical therapies for Parkinson's disease.
Burn DJ; Tröster AI
J Geriatr Psychiatry Neurol; 2004 Sep; 17(3):172-80. PubMed ID: 15312281
[TBL] [Abstract][Full Text] [Related]
12. Cognitive and behavioural impairment in Parkinson's disease.
Merims D; Freedman M
Int Rev Psychiatry; 2008 Aug; 20(4):364-73. PubMed ID: 18925485
[TBL] [Abstract][Full Text] [Related]
13. Management of neurodegenerative disorders: Parkinson's disease and Alzheimer's disease.
Pal PK; Netravathi M
J Indian Med Assoc; 2005 Mar; 103(3):168-70, 172, 174-6. PubMed ID: 16173294
[TBL] [Abstract][Full Text] [Related]
14. The patient with Parkinson's disease: part I-treating the motor symptoms; part II-treating the nonmotor symptoms.
Snyder CH; Adler CH
J Am Acad Nurse Pract; 2007 Apr; 19(4):179-97. PubMed ID: 17430539
[TBL] [Abstract][Full Text] [Related]
15. [Drug treatment is beneficial also for elderly patients with Parkinson disease. Important to consider also other co-existing diseases].
Granérus AK
Lakartidningen; 2001 Mar; 98(13):1515-23. PubMed ID: 11330147
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic use in older adults with Parkinson's disease.
Marras C; Kopp A; Qiu F; Lang AE; Sykora K; Shulman KI; Rochon PA
Mov Disord; 2007 Feb; 22(3):319-23. PubMed ID: 17149718
[TBL] [Abstract][Full Text] [Related]
17. Session 3 "Analyzer Workshop" evolution of therapeutic strategies in Parkinson's disease.
Yanagisawa N; Yamamoto M; Kikuchi S; Murata M; Ohkuma Y
J Neurol; 2004 Oct; 251 Suppl 7():vII24-30. PubMed ID: 15505751
[No Abstract] [Full Text] [Related]
18. Drugs for Parkinson's Disease.
Treat Guidel Med Lett; 2004 Jun; 2(22):41-6. PubMed ID: 15529113
[No Abstract] [Full Text] [Related]
19. Assessing the impact of ease of administration and tolerability on treatment choices in Parkinson's disease.
Setter SM
Neurol Clin; 2008 Aug; 26(3 Suppl):S45-63, vi. PubMed ID: 18774442
[TBL] [Abstract][Full Text] [Related]
20. Non-completion of changes to prescribed medications in people with Parkinson's disease.
Ng WT; Caslake R; Counsell CE
Age Ageing; 2007 May; 36(3):333-6. PubMed ID: 17267451
[No Abstract] [Full Text] [Related]
[Next] [New Search]
